<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="144469">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01720485</url>
  </required_header>
  <id_info>
    <org_study_id>DPCEMS0812</org_study_id>
    <nct_id>NCT01720485</nct_id>
  </id_info>
  <brief_title>Comparison of Desloratadine Associated With Prednisolone (Tablet)Versus Dexchlorpheniramine Associated With Betamethasone (Tablet) for Adult Persistent Allergic Rhinitis Treatment</brief_title>
  <official_title>A Double-blind,Double Dummy, Randomized, Multicenter Parallel-group Study on Efficacy of Desloratadine and Prednisolone Association Compared to Dexchlorpheniramine and Betamethasone Association in Adults With Moderate - Severe Persistent Allergic Rhinitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EMS</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>EMS</source>
  <oversight_info>
    <authority>Brazil: National Health Surveillance Agency</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the non-inferiority clinical efficacy of two
      different drug associations in the treatment of Moderate - Severe Persistent Allergic
      Rhinitis in Adults.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">March 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Efficacy of treatment in persistent allergic rhinitis based on nasal symptoms score</measure>
    <time_frame>7 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The mean variability of nasal symptoms score observed between visit 1 and visit 2 will be used as the primary endpoint of clinical efficacy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety will be evaluated by the adverse events occurrences</measure>
    <time_frame>7 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Adverse events will be collected and followed in order to evaluate safety and tolerability</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">234</enrollment>
  <condition>Allergic Rhinitis</condition>
  <arm_group>
    <arm_group_label>Desloratadine + Prednisolone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patients will take 2 tablets three times a day, as follows:
Morning: 1 tablet of the test medication(Desloratadine 5 mg + Prednisolone 20 mg) + 1 tablet of placebo control medication.
Afternoon: 1 tablet of placebo test medication + 1 tablet of placebo control medication.
Night: 1 tablet of placebo test medication + 1 tablet of placebo control medication.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dexchlorpheniramine + Betamethasone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The patients will take 2 tablets three times a day, as follows:
Morning: 1 tablet of the control medication(Dexchlorpheniramine 2mg + Betamethasone 0.25mg) + 1 tablet of placebo test medication.
Afternoon: 1 tablet of the control medication(Dexchlorpheniramine 2mg + Betamethasone 0.25mg) + 1 tablet of placebo test medication.
Night: 1 tablet of the control medication(Dexchlorpheniramine 2mg + Betamethasone 0.25mg) + 1 tablet of placebo test medication.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Desloratadine + Prednisolone</intervention_name>
    <description>1 tablet 3 times a day</description>
    <arm_group_label>Desloratadine + Prednisolone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexchlorpheniramine + Betamethasone</intervention_name>
    <description>1 tablet 3 times a day</description>
    <arm_group_label>Dexchlorpheniramine + Betamethasone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed Consent of the patient;

          -  Clinical diagnosis of moderate - severe persistent allergic rhinitis according to
             ARIA classification(Allergic Rhinitis and Its Impact on Asthma);

          -  Adults aged ≥ 18 years old;

          -  Evidence of sensitization to aeroallergens in examination (immediate skin tests or
             serum specific IgE) in the 12 months prior to inclusion.

        Exclusion Criteria:

          -  Decongestants dependent patients or patients receiving allergen specific
             immunotherapy;

          -  Patients who were in use of oral antihistamines or decongestants in the past 15 days;

          -  Patients who were treated with systemic corticosteroids in the last month;

          -  Patients on treatment with monoamine oxidase inhibitors (MAOIs);

          -  Patients with history of hypersensitivity to  any of the formula compounds;

          -  Patients with any clinically significant disease that in the investigator opinion can
             not participate in the study

          -  Patients who have uncontrolled asthma, chronic sinusitis, drug related rhinitis and
             nasal anatomic abnormalities.

          -  Participation in clinical trial in 30 days prior to study entry;
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>IMA - Instituto de Pesquisa Clínica e Medicina Avançada</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fabio M Castro, MD</last_name>
      <phone>55 11 38639156</phone>
      <email>daniela.fakih@imabrasil.com</email>
    </contact>
    <investigator>
      <last_name>Fabio M Castro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>September 24, 2013</lastchanged_date>
  <firstreceived_date>October 31, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Rhinitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Betamethasone-17,21-dipropionate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Betamethasone</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Betamethasone sodium phosphate</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
    <mesh_term>Dexchlorpheniramine</mesh_term>
    <mesh_term>Chlorpheniramine</mesh_term>
    <mesh_term>Desloratadine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
